AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
October 05, 2022 09:00 ET
|
AnaptysBio, Inc.
Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancerCOSTAR, a Phase 2 trial of JEMPERLI plus...
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
September 12, 2022 07:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
August 31, 2022 16:15 ET
|
AnaptysBio, Inc.
Imsidolimab (anti-IL-36 receptor antagonist) did not demonstrate improvement over placebo in the primary endpoint and key secondary endpointsImsidolimab was safe and well tolerated with no...
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
August 08, 2022 16:05 ET
|
AnaptysBio, Inc.
Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022Top-line data from the ongoing rosnilimab...
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 05, 2022 16:00 ET
|
AnaptysBio, Inc.
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
June 02, 2022 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control...
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
May 04, 2022 16:15 ET
|
AnaptysBio, Inc.
Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022Top-line data from the ongoing imsidolimab...
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
April 27, 2022 16:15 ET
|
AnaptysBio, Inc.
ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement...
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
March 21, 2022 16:15 ET
|
AnaptysBio, Inc.
Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage antibody programs SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE)...
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
March 14, 2022 16:20 ET
|
AnaptysBio, Inc.
Imsidolimab (anti-IL-36R Ab) treatment did not demonstrate improvement over placebo in top-line primary or secondary endpointsAnaptysBio to discontinue imsidolimab clinical development in...